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Abstract
Background: Type-1 T cells are critical for effective anti-tumor immune responses. The recently discovered
microRNAs (miRs) are a large family of small regulatory RNAs that control diverse aspects of cell function, including
immune regulation. We identified miRs differentially regulated between type-1 and type-2 T cells, and determined
how the expression of such miRs is regulated.
Methods: We performed miR microarray analyses on in vitro differentiated murine T helper type-1 (Th1) and T
helper type-2 (Th2) cells to identify differentially expressed miRs. We used quantitative RT-PCR to confirm the
differential expression levels. We also used WST-1, ELISA, and flow cytometry to evaluate the survival, function and
phenotype of cells, respectively. We employed mice transgenic for the identified miRs to determine the biological
impact of miR-17-92 expression in T cells.
Results: Our initial miR microarray analyses revealed that the miR-17-92 cluster is one of the most significantly
over-expressed miR in murine Th1 cells when compared with Th2 cells. RT-PCR confirmed that the miR-17-92
cluster expression was consistently higher in Th1 cells than Th2 cells. Disruption of the IL-4 signaling through either
IL-4 neutralizing antibody or knockout of signal transducer and activator of transcription (STAT)6 reversed the miR-
17-92 cluster suppression in Th2 cells. Furthermore, T cells from tumor bearing mice and glioma patients had
decreased levels of miR-17-92 when compared with cells from non-tumor bearing counterparts. CD4
+ T cells
derived from miR-17-92 transgenic mice demonstrated superior type-1 phenotype with increased IFN-g production
and very late antigen (VLA)-4 expression when compared with counterparts derived from wild type mice. Human
Jurkat T cells ectopically expressing increased levels of miR-17-92 cluster members demonstrated increased IL-2
production and resistance to activation-induced cell death (AICD).
Conclusion: The type-2-skewing tumor microenvironment induces the down-regulation of miR-17-92 expression in
T cells, thereby diminishing the persistence of tumor-specific T cells and tumor control. Genetic engineering of T
cells to express miR-17-92 may represent a promising approach for cancer immunotherapy.
Background
We have focused on the development of effective immu-
notherapeutic strategies for central nervous system
(CNS) tumors, such as glioblastoma multiforme (GBM).
Preclinical studies have demonstrated that tumor-speci-
fic T helper type-1 (Th1) and T cytotoxic type-1 (Tc1)
cells, but not type-2 counterparts, can efficiently traffic
into CNS tumor sites and mediate effective therapeutic
efficacy, recruited via the type-1 chemokine CXCL10
[1-3] and the integrin receptor, Very Late Antigen
(VLA)-4 [4-7]. Despite the importance of the type-1 T
cell response, cancers, including GBMs, secrete numer-
ous type-2 cytokines [8-10] that promote tumor prolif-
eration [11,12] and immune escape [13]. Hence, the
strategic skewing of existing type-2 to type-1 immunity
in glioma patients may be critical for the development
of more effective immunotherapy.
MicroRNAs (miRs) are a novel class of endogenous
small single-stranded RNA molecules which are 18-24
nucleotides in length [14]. Mature miRs repress mRNA
encoded protein translation and are highly conserved
between species, including viruses, plants and animals
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genome that collectively are predicted to regulate two-
thirds of all mRNA transcripts [14]. Findings over the
past several years strongly support a role for miRs in
the regulation of crucial biological processes, such as:
cellular proliferation [16], apoptosis [17], development
[18], differentiation [19], metabolism [20], and immune
regulation [21,22]. We recently reported that miR-222
and -339 in cancer cells down-regulate the expression of
an intercellular cell adhesion molecule (ICAM)-1,
thereby regulating the susceptibility of cancer cells to
cytotoxic T lymphocytes (CTLs) [23]. This is among the
first reports to demonstrate the role of miR in cancer
immunosurveillance.
In the current study, in an effort to understand the
potential roles of miRs in anti-tumor immunity, we
examined miRs differentially expressed in Th1 and Th2
cells. Our miR microarray and RT-PCR analyses revealed
that of all analyzed miRs, members of the miR-17-92
cluster (miR-17-92) are of the most significantly over-
expressed miRs in murine Th1 cells when compared with
Th2 cells. The miR-17-92 transcript encoded by mouse
chromosome14 (and human chromosome 13) is the pre-
cursor for 7 mature miRs (miR-17-5p, miR-17-3p, miR-
18a, miR-19a, miR-20a, miR-19b and miR-92) [24,25].
This cluster is also homologous to the miR-106a-363
cluster on the X chromosome and the miR-106b-25 clus-
ter on chromosome 5. Together, these three clusters con-
tain 15 miR stem-loops, giving rise to 14 distinct mature
miRs that fall into 5 miR families. The members in each
family have identical seed regions. This genomic organi-
zation is highly conserved in all vertebrates for which
complete genome sequences are available [26].
miRs in the miR-17-92 cluster are amplified in various
tumor types, including B cell lymphoma and lung cancer,
and promote proliferation and confer anti-apoptotic func-
tion in tumors, thereby promoting tumor-progression
[27-31]. Knockout and transgenic studies of the miR-17-
92 cluster in mice have demonstrated the importance of
this cluster in mammalian biology [25]. Transgenic mice
with miR-17-92 overexpressed in lymphocytes develop
lymphoproliferative disorder and autoimmunity but not
cancer [24]. These findings demonstrate a critical role for
miR-17-92 cluster in T cell biology.
We show here that miR-17-92 is up-regulated in Th1
cells when compared with Th2 cells. IL-4 and STAT6
signaling mediate the down-regulation of miR-17-92.
Tumor-bearing host conditions also suppress the miR-
17-92 cluster expression in T cells, which is associated
with a loss in ability to produce IFN-g. This led us to
hypothesize that miR-17-92 cluster overexpression
might enhance type-1 responses. Indeed, type-1 T cells
derived from miR-17-92 transgenic mice demonstrated a
more pronounced type 1 phenotype including enhanced
IFN-g production and increased VLA-4 expression when
compared with control type-1 T cells. These findings
suggest that miR-17-92 plays a critical role in type-1
adaptive immunity.
Materials and methods
Reagents
RPMI 1640, FBS, L-glutamine, sodium pyruvate, 2-mer-
captoethanol, nonessential amino acids, and penicillin/
streptomycin were obtained from Invitrogen Life Tech-
nologies. Recombinant murine (rm) IL-12 was pur-
chased from Cell Sciences Technologies. RmIL-4,
recombinant human (rh) IL-4 and rhIL-2 were pur-
chased from PeproTech. Purified monoclonal antibodies
(mAbs) against IL-12 (C15.6), IFN-g (R4-6A2), IL-4
(11B11), CD3 (145-2C11), CD4 (RM4-5), CD8 (53-6.7)
and CD49d (R1-2) were all purchased from BD Phar-
mingen. Purified mAbs against CD3 (UCHT1) and
CD28 (CD28.2) and IL-4 (MP4-25D2) were purchased
from Biolegend. RT-PCR reagents and primers were
purchased from Applied Biosystems and analyzed on a
BioRad IQ5. WST-1 reagent was purchased from Roche.
For isolation of T cells, immunomagenic isolation kits
from Miltenyi Biotec were used. All reagents and vectors
for lentiviral production were purchased from System
Biosciences with the exception of Lipofectamine 2000,
which was from Invitrogen.
Mice
C57BL/6 mice and C57BL/6 background STAT6 defi-
cient mice (B6.129S2 [C]-Stat6
tm1Gru/J; The Jackson lab)
(both 5-9 wk of age) were purchased from The Jackson
Laboratory. C57BL/6-background miR-17-92 transgenic
(TG) mice (C57BL/6-Gt [ROSA]26Sor
tm3(CAG-MIRN17-92,-
EGFP)Rsky/J; The Jackson Lab) were maintained in the
Hillman Cancer Center Animal Facility at University of
Pittsburgh as breeding colonies and bred to C57BL/6-
background mice transgenic for Cre recombinase gene
under the control of the Lck promoter (B6.Cg-Tg [Lck-
cre]548Jxm/J, the Jackson Lab) to obtain mice, in which
T cells expressed miR-17-92 at high levels (miR-17-92
TG/TG). For mouse tumor experiments, C57BL/6 mice
and C57BL/6 background STAT6
-/- mice received sub-
cutaneous injection of 1 × 10
6 B16 tumor cells resus-
pended in PBS into the right flank. On day 15 following
tumor inoculation, mice were sacrificed and splenic T
cells were isolated. Animals were handled in the Hill-
man Cancer Center Animal Facility at University of
Pittsburgh per an Institutional Animal Care and Use
Committee-approved protocol.
T cells from Healthy Donors and Patients with GBM
This study was approved by the local ethical review board
of University of Pittsburgh. All healthy donors and
Sasaki et al. Journal of Translational Medicine 2010, 8:17
http://www.translational-medicine.com/content/8/1/17
Page 2 of 12patients with GBM signed informed consent before blood
samples were obtained. To determine the impact of IL-4,
healthy donor-derived CD4
+ T cells were isolated with
immunomagentic-seperation and stimulated with 100 IU/
ml rhIL-2, anti-CD3 and anti-CD28 mAbs (1 μg/ml for
each) in the presence or absence of rhIL-4(10 ng/ml). RT-
PCR analyses were performed with both healthy donor-
and patient-derived T cells to determine the expression of
miR-17-92 as described in the relevant section.
Th1 and Th2 Cell Culture
Th1 and Th2 cells were differentiated from immuno-
magnetically-separated CD4
+ splenic T cells. Magnetic
activated cell separation (MACS) was carried out using
positive selection. Briefly, spleens were minced in com-
plete media, resuspended in red blood cell lysis buffer
and stained with immunomagnetically labeled anti-CD4
antibody. Cells were then washed and placed through
the magnetic column in 500 μl of MACS buffer. The
column was then washed 3 times with buffer and then
removed from the magnet and labeled cells were
extracted in 3 ml of MACS buffer.
For differentiation of T cells, purified CD4
+ cells were
stimulated in 48 well plates with anti-CD3 mAb (5 μg/
ml) in the presence of irradiated C57BL/6 spleen cells
(3000 Rad) as feeder cells. RmIL-12 (4 ng/ml), rmIFN-g
(4 ng/ml), anti-IL-4 (10 μg/ml) mAb and rhIL-2 (100
IU/ml) were added for Th1 development. Th2 cells were
generated from the same CD4
+ cell precursors stimu-
lated with anti-CD3 mAb and feeder cells in the pre-
sence of rmIL-4 (50 ng/ml), two anti-IFN-g mAbs (10
μg/ml), anti-IL-12 mAb (10 μg/ml) and rhIL-2 (100 IU/
mL). After 10 days cells were stained for IL-4 and IFN-g
to confirm differentiation. Neutral cell culture included
anti-CD3, feeder cells and rhIL-2. For studies involving
IL-4 blockade, 12.5 ng/ml anti-human IL-4 mAb (Biole-
gend) was used in human experiments and 2.5 μg/ml
anti-mouse IL-4 mAb (11B11) in murine studies. IFN-g
and IL-4 in the culture supernatants were measured
using specific ELISA kits (R&D Systems). For FACs ana-
lysis, cells were incubated with mAb at 4°C for 30 min,
washed twice in staining buffer, and fixed in 500 μlo f
2% paraformaldehyde in PBS. Cells were stored in the
dark at 4°C until analysis. Flow cytometry was carried
out on the Coulter XL four-color flow cytometer at the
flow cytometry core facility of the University of Pitts-
burgh Cancer Institute.
miR Microarray
Total RNA was isolated from Th1 and Th2 cells using
the Trizol reagent and quality was confirmed with an
A260/A280 ratio greater than 1.85. Two μgo ft o t a l
RNA was labeled with either Hy5 (red; Th1) or Hy3
(green; Th2) fluorescent dyes using miRCURY LNA
microRNA labeling kit (Exiqon, Woburn, MA) accord-
ing to manufacturer’s protocol. Labeled miR samples in
duplicate were cohybridized on to miR array slides, a
custom spotted miR array V4P4 containing duplicated
713 human, mammalian and viral mature antisense
microRNA species (miRBase: http://microrna.sanger.ac.
uk/, version 9.1) plus 2 internal controls with 7 serial
dilutions printed in house (Immunogenetics Laboratory,
Department of Transfusion Medicine, Clinical Center,
National Institutes of Health) [32]. After washing, raw
intensity data were obtained by scanning the chips with
GenePix scanner Pro 4.0 and were normalized by med-
ian over entire array. Differentially expressed miRs were
d e f i n e db ym e a n( n=2 )f o l dc h a n g e( T h 1 / T h 2s i g n a l
intensity) >2.
Quantitative RT-PCR
Total RNA was extracted using the Qiagen RNeasy kit
and quality was confirmed with a A260/A280 ration
greater than 1.85. RNA was subjected to RT-PCR analy-
sis using the TaqMan microRNA Reverse Transcription
Kit, microRNA Assays (Applied Biosystems), and the
Real-Time thermocycler iQ5 (Bio-Rad). The small
nucleolar SNO202 was used as the housekeeping small
RNA reference gene for all murine samples and RNU43
for human samples. All reactions were done in triplicate
and relative expression of RNAs was calculated using
the ΔΔCT method [33].
WST-1 Proliferation Assay
For WST-1 proliferation assays, 1 × 10
4 cells were cul-
tured in a 96 well plate for 24-48 hours in 100 μlo f
complete media. Then, 10 μl of WST-1 reagent was
added to each well. Cells were incubated at 37°C, 5%
CO2 for 4 hours, and placed on a shaker for 1 min. The
plates were then read on a micro plate reader with a
wavelength of 420 nm and a reference at 620 nm.
Assays using Jurkat lymphoma cells transduced with
miR-17-92
Jurkat human T cell leukemia cells (American Type
Culture Collection) were transduced by either one of
the following pseudotype lentiviral vectors: 1) control
vector encoding GFP; 2) the 17-92-1 expression vector
encoding miR-17 18 and 19a, or 3) the 17-92-2 expres-
sion vector encoding miR 20, 19b-1, and 92a-1. All vec-
tors were purchased from SBI. Lentiviral particles were
produced by co-transfecting confluent 293TN cells (SBI)
with pPACK-H1 Lentivirus Packaging Kit (SBI) and the
miR containing expression vectors (SBI) noted above
using Lipofectamine 2000 reagent (Invitrogen). Superna-
tant was collected after 48 hour incubation at 37°C with
5% CO2 and placed at 4°C with PEG-it Virus Concen-
tration Solution (SBI) for 24 hrs. Supernatants/PEG
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resuspended in a reduced volume of media as viral
stock. Jurkat cells were further resuspended in the viral
stock together with polybrene (8 μg/ml) for 24 hrs.
Fresh media was then added to the cells and transduc-
tion efficiency was evaluated by GFP expressing cells.
For IL-2 production, transduced Jurkat cells were stimu-
lated with Phorbol 12-myristate 13-acetate (PMA) (10
ng/ml) and ionomycin (500 nM) for overnight and
supernatant was assayed for IL-2 by a human IL-2
ELIZA kit. For activation induced cell death (AICD),
cells were treated with 10 μg/ml purified anti-CD3 mAb
(UCHT1) from Biolegend for 24 hours and then cell via-
bility was measured using WST-1 reagent.
Statistical Methods
All statistical analyses were carried out on Graphpad
Prism software. The statistical significance of differences
between groups was determined using student t- test.
We considered differences significant when p < 0.05. A
post test for linear trend test was used to determine lin-
ear trend and we considered p < 0.05 to be significant.
Results
miR-17-92 and its paralogs are overexpressed in Th1 cells
compared with Th2 cells
To identify differentially expressed miRs between Th1
and Th2 cells, we performed a miR microarray analysis.
From mouse splenic CD4
+ T cells, Th1 and Th2 cells
were generated as described in Materials and Methods.
These T cells exhibited expected cytokine profiles with
Th1 cells dominantly producing IFN-g but not IL-4,
while Th2 cells produce mostly IL-4 (Fig. 1A). Total
RNA was extracted from these T cells, and analyzed for
differential miR expression by miR microarray for 714
miRs (Fig. 1B). Hierarchical clustering of differentially
expressed miRs revealed distinct miR expression profiles
between the Th1 and Th2 cells. Eleven of the miRs
from the miR-17-92 cluster and its paralogs were
expressed at higher levels in Th1 cells than in Th2 cells.
Next, we ranked the miRs preferentially expressed in
Th1 cells according to the fold difference of expression
when compared with Th2 cells (Fig. 1C). Interestingly,
members of miRs in the miR-17-92 clusters were identi-
fied as the most differentially expressed of all miRs in
Figure 1 Microarray analysis demonstrates up-regulation of miR-17-92 in Th1 cells. (A), Intracellular IFN-g vs. IL-4 expression of Th1 and
Th2 cells induced from mouse CD4
+ splenic T cells in vitro. (B), Differentially expressed miRs were analyzed by hierarchical clustering of the log2
value of Th1/Th2 pair of miR microarray signal. Red indicates up-regulation in Th1; green, up-regulation in Th2. (C), miRs were ranked by relative
fold expression in Th1/Th2 cells. Arrows indicate members of the miR-17-92 cluster or paralog clusters. miRs with a relative expression of >2.35
fold in Th1 are shown. (B and C), hsa- and mmu- indicate human and mouse miR probes, respectively. Hsa-probes can hybridize with most
mouse miR due to the high homology and mmu-signals are shown only when murine miR has unique sequence compared to its human
counterpart. (D), Ideogram of mouse chromosome 14 showing the location and order of the miR-17-92 cluster (adapted from NCBI Blast).
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ters appear to be transcribed as single polycistronic
transcripts (Fig. 1D), we expected that all the miRs from
the miR-17-92 cluster would be consistently expressed
at higher levels in Th1 cells than in Th2 cells, which
was confirmed by RT-PCR analysis (Fig. 2A).
The miR-17-92 cluster has 2 paralog clusters: miR-
106a-363 and miR-106b-25. These paralog clusters tar-
get similar mRNAs as the miR-17-92 cluster due to high
sequence homology [34]. To establish if these paralog
miR clusters are also overexpressed in our Th1 vs. Th2
cells, we next performed RT-PCR for miRs in each of
these clusters. Representative for these paralog clusters
are miR-106a and miR106b (Fig. 2B). These data
demonstrate that the paralog clusters of miRs were also
up-regulated in Th1 cells over Th2.
Neutralization of endogenous IL-4 up-regulates miR-17-92
cluster miRs in T-cells
In order to identify factors that contribute to the differ-
ential expression of miR-17-92 cluster miRs between
Th1 and Th2 cells, we next sought to determine
whether a prototypical type-2 inducing cytokine, IL-4,
would affect miR-17-92 expression in CD4
+ T cells.
Neutralization of endogenous IL-4 by specific mAb
against IL-4 up-regulated miR-17-92 cluster miRs in
CD4
+ T cells stimulated with IL-2 without addition of
Th1-inducing factors IL-12 or IFN-g, by approximately
50% (Fig. 3A). The anti-IL-4 mAb also up-regulated
miR-17-92 in Th2 culture conditions as well (data not
shown). To determine whether there is an IL-4 dose-
dependent suppression of miR-17-92 cluster, we next
treated CD4
+ T cells with increasing doses of IL-4 at 0,
10, 50 or 100 ng/ml and measured miR-17-5p expres-
sion by RT-PCR (Fig. 3B). miR-17-92 suppression was a
dose-dependent phenomenon.
Up-regulated miR-17-92 expression in STAT6 deficient
T cells
To further elucidate the effect of IL-4 signaling on miR-
17-92 cluster expression, we next cultured CD4
+ T cells
under Th1 or Th2 skewing conditions from mice deficient
Figure 2 Enhanced expression of miRs from the miR-17-92 cluster in Th1 cells. Data represent relative expression of mature miRs in Th1
compared with Th2 cells. SNO202 was used as the internal control and ΔΔCT method was used to examine expression relative to the Th2 cell
value. Relative expression is shown for (A), miR-17-92 cluster members or (B), representative paralog cluster members, miR-106a and -106b. Error
Bars indicate standard deviation of the triplicate samples. Each experiment was repeated at least 3 times. Up-regulation in Th1 vs. Th2 is
significant in (A) with p < .01 for miR-92 and p < .0001 for all other miRs and in (B), with p < .001 for miR-106a and p < .05 for miR106b using
the student t test.
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Th1 and Th2 cultured cells induced from STAT6-deficient
mice showed higher levels of miR-17-5p expression com-
pared with corresponding WT Th cells, suggesting a novel
critical role of IL-4R/STAT6-signaling in the down-regula-
tion of miR-17 expression (Fig. 3C).
Suppression of miR-17-92 may occur in
cancer-bearing hosts
These data led us to hypothesize that suppression of
miR-17-92 would occur in cancer-bearing hosts where
tumor-derived factors likely promote Th2-skewed
immune responses and secretion of IL-4 [8]. Indeed,
CD4
+ and CD8
+ splenocytes (SPCs) derived from wild
type C57BL/6 mice bearing B16 subcutaneous tumors
expressed lower levels of miR-17-5p when compared
with those derived from non-tumor bearing mice (Fig.
4A). Interestingly, the tumor bearing condition did not
suppress miR-17-5p expression by CD4
+ T cells in
STAT6
-/- mice. Furthermore, CD8
+ T cells in STAT6
-/-
mice demonstrated enhanced levels of miR-17-5p
expression when these mice bore B16 tumors compared
with non-tumor bearing mice. When wild type CD4
+
T cells were stimulated with anti-CD3 mAb in vitro for
24 hours, the CD4
+ T cells from tumor-bearing mice
produced lower levels of IFN-g when compared with
ones from non-tumor bearing wild type mice (Fig. 4B).
These data suggest that tumor-associated immunosup-
pression may involve the down-regulation of miR-17-92
through a STAT6 dependant pathway.
Figure 3 Modulation of miR-17-92 expression by IL-4 signaling. (A) Immuno-magnetically isolated mouse splenic CD4
+ T cells were cultured
with 5 μg/ml plated anti-CD3, feeder cells and 100 U/ml hIL-2 ("Neutral” condition). Anti-IL-4 (2.5 μg/ml) or isotype control mAb was added to
the appropriate wells and cultured for 5 days prior to extraction of total RNA. Statistical analysis was carried out using the student t test. The
blockade of IL-4 up-regulated miR-17-5p and miR-92 significantly with p < .001 and p < .005, respectively. (B), CD4
+ T cells were cultured with
anti-CD3, feeder cells, and hIL-2 and varying amounts of IL-4 for 5 days. Total RNA was extracted and analyzed by RT-PCR for miR-17-5p
expression. The dose dependent decrease of miR-17-92 expression was analyzed using post test for linear trend and was significant (p < .001).
(C), Th1 and Th2 cells were induced from splenic CD4
+ T cells isolated from either wild-type or STAT6
-/- mice. Total RNA was extracted and RT-
PCR was performed using specific primers against miR-17-5p and miR-92. Columns represent the mean of triplicates from one of 2 two
experiments with similar results, and error bars represent standard deviations. STAT6
-/- cells demonstrated significantly higher levels of miR-17-5p
and miR-92 compared with wild type (WT) cells in both Th1 and Th2 conditions (p < .001) using the student t test.
Sasaki et al. Journal of Translational Medicine 2010, 8:17
http://www.translational-medicine.com/content/8/1/17
Page 6 of 12We next evaluated whether the observed IL-4-
mediated and tumor-induced suppression of miR-17-
92 are relevant in human T cells. When healthy
donor-derived CD4
+ T cells were stimulated with rhIL-
2, anti-CD3 and anti-CD28 mAbs, consistent with the
mouse data, addition of rhIL-4 in the cultures sup-
pressed expression of miR-17-5p (Fig. 4C). Moreover,
CD4
+ T cells obtained from patients with GBM exhib-
ited significantly decreased levels of miR-17-5p when
compared with ones from healthy donors (Fig. 4D).
Thus both IL-4 and GBM-bearing conditions suppress
m i R - 1 7 - 5 pe x p r e s s i o ni nC D 4
+ T cells. Although not
statistically significant, CD8
+ T cells demonstrated a
trend towards decreased levels of miR-17-5p expres-
sion in GBM patients when compared with healthy
donors (Fig. 4D).
T cells derived from miR-17-92 transgenic mice display
enhanced type-1 phenotype
The data discussed above strongly suggest GBM-asso-
ciated factors and a type-2 promoting cytokine (IL-4)
down-regulate miR-17-92 in T cells. miR-17-92 is
expected to play pivotal roles in T cell functions. We
therefore sought to determine whether ectopic expres-
sion of miR-17-92 would promote the type-1 phenotype
of T cells. As detailed in Materials and Methods, we
produced mice that overexpress miR-17-92 specifically
in T cells (miR-17-92 TG/TG). We isolated CD4
+ sple-
nocytes from these mice and evaluated the expression of
miR-17-5p (Fig. 5A). CD4
+ cells from TG/TG mice dis-
played a greater than 15 fold increase in miR-17-p5
expression as compared with controls. These cells also
expressed elevated levels of CD49d, which is a subunit
Figure 4 Tumor bearing conditions down-regulate miR-17-5p expression in T cells. SPCs were harvested from C57BL/6 or STAT6
-/- mice
bearing day 15 subcutaneous B16 melanoma (T+) or control non-tumor bearing mice (T-). (A), CD4
+ and CD8
+ T cells were isolated by
immuno-magnetic bead separation, and evaluated for miR17-5p expression. (B),1×1 0
6 CD4
+ cells from WT mice were briefly stimulated with
anti-CD3 mAb for 6 hours. Concentration of IFN-g secreted in culture media was evaluated by specific ELISA. (C), CD4
+ T cells were isolated from
healthy donor-derived peripheral blood mononuclear cells (PBMC) and stimulated with 5 μg/ml plated anti-CD3, feeder cells (irradiated PBMC)
and 100 IU/ml hIL2 in the presence or absence of hIL-4 (10 ng/ml) for 5 days prior to extraction of total RNA. (D), Non-stimulated CD4
+ and
CD8
+ T cells were isolated by immuno-magnetic beads from PBMC derived from healthy donors (n = 6) or patients with GBM (n = 8) and miR-
17-5p expression was analyzed by RT-PCR. Data in (A), (B) and (C), are representative of 2 identical experiments with similar results. Columns
represent the mean of triplicates from a single experiment and error bars represent standard deviation. * indicates p < 0.01 and ** indicates p <
0.05 between the two groups using the student t test.
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Although CD49d (also known as a4-integrin) can form
heterodimers with both b1( C D 2 9 )a n db7 integrins,
a4b7 complexes were not expressed by either Th1 cells
or Th2 cells, suggesting that CD49d is a suitable surro-
gate for VLA-4 expression levels [4-7]. miR-17-92-TG/
TG CD4
+ cells also demonstrated enhanced ability to
produce IFN-g upon stimulation (Fig. 5C). Similar data
were obtained with CD8
+ T cells isolated from these
TG/TG mice (data not shown). These findings suggest
that miR-17-92 promotes the type-1 phenotype in differ-
entiating T cells.
Ectopic expression of miR-17-92 promotes IL-2
production and resistance against activation-induced
cell death (AICD) in Jurkat cells
miR-17-92 is expected to play pivotal roles in T cell sur-
vival as well as functions. To evaluate these aspects, we
transduced Jurkat cells with lentiviral vectors encoding
green fluorescence protein (GFP) and either the miR-
17-92-1 expression vector encoding miR-17 18 and 19a,
or the 17-92-2 expression vector encoding miR 20, 19b,
and 92. The control vector encodes GFP, but not miRs.
Transduced Jurkat cells were stimulated with PMA and
ionomycin for overnight before the supernatants were
assayed for IL-2 production by ELISA (Fig. 6A). Trans-
duction of either miR-vector promoted IL-2 production
in Jurkat cells.
AICD and chemotherapy-induced suppression of T
cells represent major obstacles for efficient T cell-based
cancer immunotherapy [36,37]. We next examined
whether transfection of Jurkat cells with miR-17-92 con-
fers T cells resistant to AICD. AICD was induced by
cultivation of Jurkat cells in the presence of 10 μg/ml
anti-CD3 mAb, which is hyper-stimulatory and used as
a standard method to induce AICD [38]. As demon-
strated in (Fig. 6B), the growth of control Jurkat cells
was significantly suppressed by nearly 25% in the AICD
inducing condition compared with the same cells with
the regular (growth-promoting) dose of anti-CD3 mAb
(1 μg/ml). In contrast, the growth of Jurkat cells trans-
duced with either miR-17-92-1 or miR-17-92-2 was not
significantly altered by the high dose (10 μg/ml) of anti-
CD3 mAb, suggesting that the miR-17-92 transfection
confers T cells with substantial resistance against AICD.
These findings point to a potential utility for miR-17-92
transfected T cells in cancer immunotherapy.
Discussion
Attaining effective tumor immunity is a major goal of
modern biologic therapy, limited by the tumor microen-
vironment and profound regulatory mechanisms limiting
T cell and NK cell effectors. Here we show that the
type-2-skewing tumor microenvironment induces down-
regulation of miR-17-92 expression in T cells, thereby
hampering anti-tumor T cell responses. It also suggests
Figure 5 T cells from miR-17-92 transgenic mice demonstrate enhanced Th1 phenotype. Splenic CD4
+ T cells were immuno-magnetically
isolated from miR-17-92 TG/TG or control animals. (A), miR-17-5p expression was analyzed in total RNA extracted from these freshly isolated
cells. (B), Flow analysis was carried out on these freshly isolated cells for surface expression of CD49d, a subunit composing VLA-4. The grey-
shaded region represents CD4
+ T cells isolated from control wild type animals and the unshaded region with the solid line represents CD4
+ T
cells from miR-17-92 TG/TG mice. Dotted lines represent samples stained with isotype control Rat IgG2b. As the background staining with the
isotype IgG2b was equally very low in the two cell types, the corresponding histograms are barely distinguishable each other. (C), Isolated cells
were stimulated in Th1 skewing condition for 9 days and 5 × 10
6cells were then plated in fresh media for 24 hours, at which point supernatant
was collected and analyzed for IFN-g by ELISA. Both in (A), and (C), values in the two groups were statistically different with p < .01 using the
student t test.
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transduced T cells is warranted based on our findings
demonstrating that ectopic expression of miR-17-92 in
T cells leads to improved type-1 functions, including
increased VLA-4 expression and IFN-g production.
Blockade of endogenous IL-4 by inhibitory mAb or
disruption of STAT6 signaling was sufficient to up-regu-
late miR-17-92 in T cells (Fig 3). These findings suggest
that STAT6 may negatively regulate miR-17-92 expres-
sion in T cells. Several transcription factors have been
identified that regulate expression of this miR cluster,
including the E2 transcription factor (E2F) family mem-
bers [39,40], c-Myc [41], STAT3 [42], as well as the
sonic hedgehog pathway [43,44]. How IL-4 and the
STAT6 signaling pathway negatively influence miR-17-
92 expression at a molecular level remains to be eluci-
dated. With regard to the effects of IL-4/STAT6 signal-
ing on Th1 vs. Th2 functions, we have recently
demonstrated that STAT6-/- Th2 cells exhibit Th1 phe-
notype with increased surface expression of VLA-4 [45].
These observations have led us to hypothesize that
STAT6-regulated miR-17-92 may contribute to the pro-
motion of type-1 T cell functions.
Our findings indicate that the tumor-bearing host
down-regulates miR-17-92 in T cells (Fig. 3 and 4).
Interestingly, not only are STAT6
-/- T cells resistant to
tumor-induced inhibition of miR-17-5p, but CD8
+ T
cells in tumor bearing STAT6
-/- mice exhibited higher
levels of miR-17-5p when compared with CD8
+ T cells
obtained from non-tumor bearing STAT6
-/- mice. In
addition to IL-4, other tumor-derived factors are likely
to be involved in these events. Further studies are war-
ranted to elucidate the molecular mechanisms underly-
ing the regulation of miR-17-92 in T cells, especially in
the tumor microenvironment.
While tumor bearing mice demonstrated decreased
levels of miR-17-92 in both CD4
+ and CD8
+ cells,
human GBM patients exhibited a statistically significant
decrease of miR-17-92 in CD4
+ cells but not in CD8
+
cells (Fig. 4). However, there still appears to be a trend
towards lower miR-17-92 expression in GBM patient-
derived CD8
+ cells compared with those obtained from
healthy donors. The lesser degree of miR-17-92 suppres-
sion in CD8
+ cells compared with CD4
+ cells in GBM
patients is plausible based on our current understanding
of CD4
+ and CD8
+ T cell biology. The type-1 vs. type-2
differentiation appears to be more distinct for CD4
+ T
cells than for CD8
+ cells [46,47], and this may also be
the case for miR-17-92. Another speculation is that
CD8
+ T cells may be less sensitive to IL-4 than CD4
+
T cells thereby exhibiting less repression of miR-17-92.
Further studies with larger sample size are warranted.
Messages encoding proteins that are targeted by miR-
17-92 cluster miRs include: E2F1, E2F2, E2F3 [40,41],
P21 [48], anti-angiogenic thrombospondin-1 and con-
nective tissue growth factor [49], proapoptotic Bim, and
phosphatase and tensin homolog (PTEN) [24]. These
proteins are all involved in cell cycle regulation or
Figure 6 Ectopic expression of miR-17-92 cluster members in the human Jurkat T cell line confers increased IL-2 production and
resistance to AICD. Jurkat cells were transduced by either one of the following pseudo typed lentivirus vectors: 1) control vector encoding
GFP; 2) the 17-92-1 expression vector encoding miR-17 18 and 19a, or 3) the 17-92-2 expression vector encoding miR 20, 19b-1, and 92a-1. (A),
Transduced Jurkat cells (5 × 10
4) in the triplicate wells were stimulated with PMA (10 ng/ml) and ionomycin (500 nM) for overnight and
supernatant was harvested and tested for the presence of IL-2 by specific ELISA. The figure shows mean values and standard deviations of the
amount of IL-2 released from each group. Statistical analysis was carried out using the student t test, and significant (p < .005) increase of IL-2
production was confirmed in both 17-92-1 and the 17-92-2 transduced groups compared with the control group. (B), Transduced Jurkat cells
were treated with the AICD inducing condition (10 μg/ml anti-CD3 mAb) or in complete media (No Tx) for 24 hrs. Then, the relative numbers of
viable cells were evaluated by 4 hour WST-1 assays. The figure shows mean values and standard deviations of 8 wells/group each containing 5
×1 0
5 cells. For each group, the relative OD readings at 450 nm of AICD-treated cells compared with control Jurkat cells without AICD-treatment
is indicated. * indicates p < 0.05 between the two groups using student t test.
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of miR-17-92 cluster in T cell biology. In fact, Bim and
PTEN are down-regulated in T cells overexpressing
miR-17-92 [24]. Furthermore, TGF-b receptor II
(TGFBRII) is one of the established targets of miR-17-
92 [50]. We are currently evaluating whether miR-17-92
transgenic T cells show down-regulated TGFBRII and
decreased sensitivity to TGF-b.
In agreement with others [24], our findings demon-
strating increased IFN-g production from miR-17-92
TG/TG T cells compared with control cells suggest that
miR-17-92 may actually promote the type-1 skewing of
T cells (Fig. 5 and 6C). As miR-17-92 targets hypoxia-
inducible factor (HIF)-1a in lung cancer cells [51],
enhanced miR-17-92 expression in activated T cells may
promote the type-1 function of T cells at least partially
through down-regulation of HIF-1a.A l t h o u g hH I F - 1
expression provides an important adaptation mechanism
of cells to low oxygen tension [52,53], it does not appear
to be critical for survival of T cells, unlike its apparent
role in macrophages [54]. T cells do not depend on
HIF-1a for survival to the same degree as macrophages
since activated T cells produce ATP by both glycolysis
and oxidative phosphorylation [55]. Rather, HIF-1a in T
cells appears to play an anti-inflammatory and tissue-
protecting role by negatively regulating T cell functions
[52,56,57]. Indeed, T cell-targeted disruption of HIF-1a
leads to increased IFN-g secretion and/or improved
effector functions [58-61]. Although available data on
gene expression profiles in Th1 and Th2 cells do not
suggest differential expression of HIF-1a mRNA
between these cell populations [62], as is often the case
in miR-mediated gene expression regulation, miR-17-92
may still regulate HIF-1a protein expression at post-
transcriptional levels. These data collectively suggest
that miR-17-92 expression in activated T cells may pro-
mote the type-1 function of T cells at least partially
through down-regulation of HIF-1a.
The human Jurkat T cell line with ecotopic expression
of miR-17-92 cluster members demonstrate increased
IL-2 production and improved viability following treat-
ment with the AICD condition (Fig. 6). The Jurkat cell
line was established from the peripheral blood of a T
cell leukemia patient in the 1970s. This cell line is often
used to recapitulate what would happen in humans T
cells as the line retains many T cell properties, such as
CD4, a T cell receptor, and ability to produce IL-2 [63].
For these reasons, we chose to use Jurkat cells in our
experiments. We recognize, on the other hand, that this
cell line has pitfalls since this is a tumor cell line with
enhanced survival compared to normal T cells due to
their intrinsic biology. Thus, continued work with
human T cells is clearly warranted.
miRs in the miR-17-92 clusters are amplified in various
tumor types including B cell lymphoma and lung cancer,
and promote proliferation and confer anti-apoptotic func-
tion in tumors, thereby promoting tumor-progression and
functioning as oncogenes [27-31]. However, miR-17-92
by itself may not be responsible for oncogenesis as trans-
genic mice with miR-17-92 overexpressed in lymphocytes
develop lymphoproliferative disorder and autoimmunity
but not cancer [24]. miR-17-92 may cooperate with other
oncogenes to promote the oncogenic process. Transgenic
mice overexpressing both miR-17-92 and c-Myc in lym-
phocytes develop early onset lymphomagenesis disorders
[27]. On the other hand, knockout studies of the miR-17-
92 cluster in mice have demonstrated the importance of
this cluster in mammalian biology. While knockout of
the miR-17-92 cluster results in immediate post-natal
death of all progeny, knockout of either or both the miR-
106a or miR-106b clusters are viable without an apparent
phenotype [64]. However knock out of the miR-17-92
cluster together with miR-106a or 106b cluster results in
embryonic lethality [25].
During lymphocyte development, miR-17-92 miRs are
highly expressed in progenitor cells, with the expression
level decreasing 2- to 3-fold following maturation [24]. In
addition, we have evaluated relative expression of miR-
17-92 in a variety of Th cells as well as naïve CD4
+ cells.
Naïve CD4
+ cells express miR-17-92 at the highest level
among the cell populations examined. Albeit lower than
that in naïve CD4
+ cells, Th1 cells express miR-17-92 at
higher levels than T neutral (anti-CD3, feeder cells and
IL-2) and Th17 cells, and Th2 cells consistently exhibit
the lowest levels of miR-17-92 among the populations
tested (data not shown). More studies are warranted on
the specific role of miR-17-92 during differentiation.
These studies reviewed above provide us with critical
insights as to what has to be expected if we develop thera-
peutic strategies by modulating miR-17-92 expression.
One major barrier for successful T cell-based cancer
immunotherapy is the low persistence of tumor antigen
(TA)-specific T cells in tumor-bearing hosts [65,66]. It
seems promising to generate genetically modified TA-spe-
cific T cells ex vivo that are resistant to tumor-mediated
immune suppression and mediate robust and long-lived
anti-tumor responses. miR-17-92 cluster has the potential
to confer resistance to tumor-derived immunosuppressive
factors and to improve type-1 reactivity. Further character-
ization of the role of miR-17-92 cluster in tumor antigen
(TA)-specific CTLs is clearly warranted and may provide
us with ability to develop novel immunotherapy strategies
with genetically engineered T cells. Additionally, identifi-
cation of diminished miR-17-92 expression in the periph-
eral blood may emerge as an important biomarker in
patients with malignancy.
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